Investment Analysts’ Recent Ratings Changes for MannKind (MNKD)

Several analysts have recently updated their ratings and price targets for MannKind (NASDAQ: MNKD):

• 8/8/2026 – MannKind was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/6/2026 – MannKind had its price target lowered by Wells Fargo & Company from $14.00 to $13.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – MannKind was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/30/2026 – MannKind had its price target raised by Wells Fargo & Company from $11.00 to $14.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – MannKind had its “buy” rating reaffirmed by HC Wainwright.
• 7/8/2026 – MannKind had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – MannKind was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/5/2026 – MannKind was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/27/2026 – MannKind was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In related news, Director Steven B. Binder sold 39,051 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $4.06, for a total value of $158,547.06. Following the transaction, the director owned 785,867 shares in the company, valued at approximately $3,190,620.02. The trade was a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).